Abstract
Background: This study aimed to: (1) Identifying KRAS mutation in ctDNA (mutKRAS ctDNA) in patients with pancreatic cancer (PC) and thoses with benign pancreatic diseases using ddPCR; (2) Investigating the association between mutKRAS ctDNA and the clinical stages of PC.
Materials and methods: 49 patients with PC and 47 patients with benign pancreatic diseases were measured mutKRAS ctDNA using ddPCR. Results: The positive mutKRAS ctDNA accounted for 69.4% in the PC group, which was statistically significantly higher than that in the benign pancreatic tumor/cyst group (21.1%) and the chronic pancreatitis group (7.1%), p<0.0001. KRAS mutant allele fraction (KRAS MAF) in ctDNA associated with the clinical stages of PC categorized by the TNM staging system, the mean KRAS MAF in ctDNA of the stage IV group was 8.4 ± 12.2%, which was statistically significantly higher than that of stage III group (2.8 ± 2.4%) and stage I-II group (1.1 ± 1.6%). The KRAS MAF had predictive significance for metastatic PC, with a cut-off value > 5.55%, AUC=0.739, p=0.019.
Conclusion: ddPCR identified a significant prevalence of patients with PC harboring mutKRAS ctDNA. The KRAS MAF in ctDNA had the prognostic value for severe progression in PC
| Published | 2025-04-24 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 15 No. 1 (2025) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2025.1.12 | |
| Keywords | ung thư tuỵ, ddPCR, KRAS, ctDNA pancreatic cancer, ddPCR, KRAS, ctDNA |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Hue Journal of Medicine and Pharmacy
Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016 Mar 3;531(7592):47–52.
Yadav DK, Bai X, Yadav RK, Singh A, Li G, Ma T, et al. Liquid biopsy in pancreatic cancer: the beginning of a new era. Oncotarget. 2018;9(42):26900–33.
Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020 Mar 1;17(3):153–68.
Wang ZY, Ding XQ, Zhu H, Wang RX, Pan XR, Tong JH. KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients. Front Oncol. 2019 Nov 29;9:1295.
Qi T, Pan M, Shi H, Wang L, Bai Y, Ge Q. Cell-Free DNA Fragmentomics: The Novel Promising Biomarker. Int J Mol Sci. 2023 Jan 1;24(2):1503.
Diaz LA, Bardelli A. Liquid biopsies: Genotyping circulating tumor DNA. Journal of Clinical Oncology. 2014 Feb 20;32(6):579–86.
Kim MK, Woo SM, Park B, Yoon KA, Kim YH, Joo J, et al. Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. Clin Chem. 2018 Apr 1;64(4):726–34.
Gardner TB, Adler DG, Forsmark CE, Sauer BG, Taylor JR, Whitcomb DC. ACG Clinical Guideline: Chronic Pancreatitis. American Journal of Gastroenterology. 2020 Mar 1;115(3):322–39.
Shimizu K, Ito T, Irisawa A, Ohtsuka T, Ohara H, Kanno A, et al. Evidence-based clinical practice guidelines for chronic pancreatitis 2021. J Gastroenterol. 2022 Oct 1;57(10):709–24.
Anaizi A, Hart PA, Conwell DL. Diagnosing Chronic Pancreatitis. Dig Dis Sci. 2017 Jul 1;62(7):1713–20.
Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MKay, et al. AJCC Cancer Staging Manual. 8th edition. New York: Springer; 2017.
Watanabe F, Suzuki K, Tamaki S, Abe I, Endo Y, Takayama Y, et al. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLoS One. 2019 Dec 1;14(12):e0227366.
Moshayedi N, Escobedo AL, Thomassian S, Osipov A, Hendifar AE. Race, sex, age, and geographic disparities in pancreatic cancer incidence. Journal of Clinical Oncology. 2022 Feb 1;40(4_suppl):520–520.
Gehrels AM, Wagner AD, Besselink MG, Verhoeven RHA, van Eijck CHJ, van Laarhoven HWM, et al. Gender differences in tumor characteristics, treatment allocation and survival in stage I–III pancreatic cancer: a nationwide study. Eur J Cancer. 2024 Jul 1;206:114117.
Samaan JS, Abboud Y, Oh J, Jiang Y, Watson R, Park K, et al. Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population- Based Study, 2000–2018. Cancers (Basel). 2023 Feb 1;15(3):870.
Huerta M, Roselló S, Sabater L, Ferrer A, Tarazona N, Roda D, et al. Circulating tumor dna detection by digital-droplet PCR in pancreatic ductal adenocarcinoma: A systematic review. Cancers (Basel). 2021 Mar 1;13(5):1–14.
Hadano N, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N, et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer. 2016 Jun 28;115(1):59–65.
Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, et al. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 2015 Oct 24;15(1):797.
Yang F, Li L, Kong XY. The Positive Feedback Loop Between Inflammation and Mutant KRAS Genes Promotes Malignant Transformation in Chronic Pancreatitis. Cancer Screening and Prevention. 2022 Dec 2;1(1):39–46.
Cheng H, Luo G, Jin K, Fan Z, Huang Q, Gong Y, et al. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients. Cancer Med. 2020 Mar;9(6):2153–9.